Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.80 |
| ▸ | TP53 | P04637 | 4/20 | 0.80 |
| ▸ | RAB9A | P51151 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RPS6KA5 | O75582 | 8/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8520141 | 0.92 | NPC1 (0.67) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7154096 | 0.91 | NPC1 (0.65) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7555014 | 0.87 | KDM4E (0.60) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7155399 | 0.86 | NPC1 (0.60) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7156031 | 0.85 | MAPT (0.58) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7155256 | 0.84 | ALDH1A1 (0.63) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8520137 | 0.82 | NPC1 (0.56) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7548704 | 0.80 | HSD17B10 (0.51) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7554486 | 0.80 | KDM4E (0.51) | NPC1TP53RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8518781 | 0.80 | NPC1 (0.52) | NPC1TP53RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | NPC1 385/4885TP53 3756/4885RAB9A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.